Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
Vascular endothelial growth factor (VEGF) is a primary stimulant of angiogenesis and is a macrophage chemotactic protein. Inhibition of VEGF is beneficial in combination with chemotherapy for some breast cancer patients. However, the mechanism by which inhibition of VEGF affects tumor growth seems t...
Saved in:
Published in | Molecular cancer therapeutics Vol. 8; no. 7; pp. 1761 - 1771 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Association for Cancer Research
01.07.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Vascular endothelial growth factor (VEGF) is a primary stimulant of angiogenesis and is a macrophage chemotactic protein.
Inhibition of VEGF is beneficial in combination with chemotherapy for some breast cancer patients. However, the mechanism
by which inhibition of VEGF affects tumor growth seems to involve more than its effect on endothelial cells. In general, increased
immune cell infiltration into breast tumors confers a worse prognosis. We have shown previously that 2C3, a mouse monoclonal
antibody that prevents VEGF from binding to VEGF receptor 2 (VEGFR2), decreases tumor growth, angiogenesis, and macrophage
infiltration into pancreatic tumors and therefore hypothesized that r84, a fully human IgG that phenocopies 2C3, would similarly
affect breast tumor growth and immune cell infiltration. In this study, we show that anti-VEGF therapy with bevacizumab, 2C3,
or r84 inhibits the growth of established orthotopic MDA-MB-231 breast tumors in severe combined immunodeficiency (SCID) mice,
reduces tumor microvessel density, limits the infiltration of tumor-associated macrophages, but is associated with elevated
numbers of tumor-associated neutrophils. In addition, we found that treatment with r84 reduced the number of CD11b + Gr1 + double-positive cells in the tumor compared with tumors from control-treated animals. These results show that selective inhibition
of VEGFR2 with an anti-VEGF antibody is sufficient for effective blockade of the protumorigenic activity of VEGF in breast
cancer xenografts. These findings further define the complex molecular interactions in the tumor microenvironment and provide
a translational tool that may be relevant to the treatment of breast cancer. [Mol Cancer Ther 2009;8(7):1761–71] |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1535-7163 1538-8514 |
DOI: | 10.1158/1535-7163.MCT-09-0280 |